CollaborationLimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7Latest NewsSwiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVaccs preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success. Read more 19 December 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/CDC_Limmatech.jpeg 533 700 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-12-19 10:33:002024-07-09 12:22:44LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7